Australian medtech investor Bioshore Ventures and US neurotechnology investor Jumpspace Ventures join Wellumio's oversubscribed pre-Series A round in the final close, supporting the next phase of clinical validation and commercialisation Wellumio, a New Zealand medical technology company developing Axana®, a portable brain imaging device for point-of-care stroke detection, today announced the final close of an oversubscribed $9.75 million pre-Series A funding round. The i

We examine Siemens Healthineers' web of eight-plus alliances — most notably its neurovascular robotics partnership with Stryker — and what it means for the acute stroke market. Our conclusion: competition in acute care is shifting from individual devices to entire care pathways, with imaging emerging as the control layer connecting screening to intervention. That shift elevates the strategic value of the upstream layer where Wellumio operates.

And why point-of-care diagnostics may be the fastest way to change it Mechanical thrombectomy is no longer an emerging therapy. It is one of the clearest advances in acute stroke care over the past decade, supported by strong clinical evidence, stable reimbursement, and broadening guideline support. In clinical terms, the debate has largely been settled. For the right patients, treated quickly enough, thrombectomy changes outcomes. And yet the market remains materially underp

Boston Scientific’s announced ~$14.5 billion acquisition of Penumbra marks one of the most significant medtech transactions in recent years. While often framed as a return to neurovascular intervention, the deeper signal is more consequential: time-critical acute care has become strategic infrastructure. For companies building upstream of intervention, the implications are material. From portfolio category to strategic necessity More than a decade ago, Boston Scientific exite

WERNEUCHEN, GERMANY & MELBOURNE, AUSTRALIA MEYTEC, a leader in telemedicine and mobile emergency care technologies, and Wellumio, an...